Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
This emerging Bitcoin infrastructure company is building a vertically integrated model (click to learn more) Laser Photonics Announces Strategic Milestone on Advanced Laser Shield Anti Drone System (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Breaking & Recent News Eton Pharmaceuticals Inc ETON

Healthcare Drug Manufacturers - Specialty & Generic
Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid... see more

Recent & Breaking News (NDAQ:ETON)

Eton Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results

GlobeNewswire March 19, 2026

Eton Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, March 19, 2026

GlobeNewswire March 3, 2026

Eton Pharmaceuticals Expands Rare Disease Portfolio Through Acquisition of U.S. Commercialization Rights to HEMANGEOL® (propranolol hydrochloride) Oral Solution

GlobeNewswire March 2, 2026

Eton Pharmaceuticals Announces U.S. FDA Approval for DESMODA(TM) (desmopressin acetate) Oral Solution

GlobeNewswire February 25, 2026

Eton Pharmaceuticals to Participate at Leerink Partners Global Healthcare Conference on Wednesday, March 11th

GlobeNewswire February 20, 2026

Eton Pharmaceuticals Announces Licensing of Rare Disease Product Candidate

GlobeNewswire February 2, 2026

Eton Pharmaceuticals to Present at Piper Sandler 37th Annual Healthcare Conference on December 4th

GlobeNewswire November 24, 2025

Eton Pharmaceuticals to Participate at 16th Annual Craig-Hallum Alpha Select Conference on November 18th

GlobeNewswire November 12, 2025

Eton Pharmaceuticals Reports Third Quarter 2025 Financial Results

GlobeNewswire November 6, 2025

Eton Pharmaceuticals to Report Third Quarter 2025 Financial Results on Thursday, November 6, 2025

GlobeNewswire October 23, 2025

Eton Pharmaceuticals to Participate at 2025 Wells Fargo Healthcare Conference

GlobeNewswire August 20, 2025

Eton Pharmaceuticals Reports Second Quarter 2025 Financial Results

GlobeNewswire August 7, 2025

Eton Pharmaceuticals to Report Second Quarter 2025 Financial Results on Thursday, August 7, 2025

GlobeNewswire July 28, 2025

Eton Pharmaceuticals Announces FDA Acceptance of New Drug Application for ET-600 (Desmopressin Oral Solution)

GlobeNewswire July 8, 2025

Eton Pharmaceuticals Announces Addition to Russell 2000® and Russell 3000® Indexes

GlobeNewswire June 27, 2025

Eton Pharmaceuticals Announces U.S. FDA Approval for KHINDIVI(TM) (hydrocortisone) Oral Solution

GlobeNewswire May 28, 2025

Eton Pharmaceuticals to Participate at Upcoming Investor Conferences

GlobeNewswire May 14, 2025

Eton Pharmaceuticals Reports First Quarter 2025 Financial Results

GlobeNewswire May 13, 2025

Eton Pharmaceuticals to Report First Quarter 2025 Financial Results on Tuesday, May 13, 2025

GlobeNewswire May 1, 2025

Eton Pharmaceuticals Announces Submission of NDA for ET-600 (Desmopressin Oral Solution)

GlobeNewswire April 28, 2025

Podcasts